Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises STARK Group with its acquisition of FagFlis Group
Mandate

Vinge advises STARK Group with its acquisition of FagFlis Group

November 07, 2022 Banking and Finance EU, Competition and Regulatory Employment and Benefits Commercial Agreements M&A Real Estate and Construction

Vinge has advised STARK Group in connection with its acquisition of the Nordic tiles actor FagFlis Group with its Swedish operation FF Kakel AB. The group has conducted operations since 1981 and includes, in addition to the Swedish stores, approximately 30 facilities in Norway with total turnover of approximately NOK 750 million.

The transaction is estimated to be completed around the turn of the year 2022/2023, following approval by the Norwegian Competition Agency.

Vinge’s team consisted of, among others,  Jonas Bergström, Joacim Rydergård, Ellinor Wargenbrant and Tobias Onegård Karlsson (M&A), Frida Ställborn (Real Estate), Hedvig Ekdahl (Commercial Contracts), Ebba Svenburg (Employment Law), Karl-Gustaw Tobola (Banking and Finance), Sebastian Örndahl and Adam Löfquist (Competition Law) and Anna Ekdahl Roos (Project Assistant).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025